Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Marker Therapeutics (Nasdaq: MRKR) announced the appointment of Kathryn Penkus Corzo to its Board of Directors, effective November 1, 2025.
Ms. Penkus Corzo brings more than 30 years of biopharma leadership across R&D, clinical development, regulatory approvals, commercialization, and corporate strategy. She most recently served as President and COO at bit.bio and previously led oncology cell therapy development at Takeda Ventures, with senior roles at Sanofi Genzyme, Roche, Eli Lilly, and Syndax.
Company leadership said the appointment strengthens the board as Marker advances its lead asset MT-601 and the APOLLO program toward a potential pivotal study in patients with CAR-relapsed diffuse large B-cell lymphoma (DLBCL).
Marker Therapeutics (Nasdaq: MRKR) ha annunciato la nomina di Kathryn Penkus Corzo nel suo Consiglio di Amministrazione, con effetto dall'1 novembre 2025.
La signora Penkus Corzo porta con sé oltre 30 anni di leadership nel settore biopharma, tra R&S, sviluppo clinico, approvazioni regolatorie, commercializzazione e strategia aziendale. Ha ricoperto recentemente il ruolo di Presidente e COO di bit.bio e in precedenza ha guidato lo sviluppo delle terapie cellulari oncologiche presso Takeda Ventures, con ruoli di livello senior presso Sanofi Genzyme, Roche, Eli Lilly e Syndax.
La direzione dell'azienda ha dichiarato che la nomina rafforza il consiglio mentre Marker avanza con il lead asset MT-601 e il programma APOLLO verso uno studio potenzialmente chiave nei pazienti con linfoma diffuso a grandi cellule B recidivante al CAR (DLBCL).
Marker Therapeutics (Nasdaq: MRKR) anunció el nombramiento de la señora Kathryn Penkus Corzo para su Junta Directiva, con efecto a partir del 1 de noviembre de 2025.
La Sra. Penkus Corzo aporta más de 30 años de liderazgo en biopharma en áreas como I+D, desarrollo clínico, aprobaciones regulatorias, comercialización y estrategia corporativa. Recientemente se desempeñó como Presidenta y COO de bit.bio y, anteriormente, dirigió el desarrollo de terapias celulares oncológicas en Takeda Ventures, con cargos de alto nivel en Sanofi Genzyme, Roche, Eli Lilly y Syndax.
La dirección de la empresa declaró que el nombramiento fortalece la junta a medida que Marker avanza con su principal activo MT-601 y el programa APOLLO hacia un posible estudio pivotal en pacientes con linfoma difuso de células B grandes recidivado al CAR (DLBCL).
Marker Therapeutics (Nasdaq: MRKR)가 2025년 11월 1일부로 발효되는 이사회에 Kathryn Penkus Corzo를 임명했다고 발표했습니다.
Penkus Corzo 여사는 연구개발(R&D), 임상개발, 규제승인, 상용화 및 기업 전략에 걸친 생명과학 분야에서 30년 이상의 리더십을 보유하고 있습니다. 최근 bit.bio의 사장 겸 최고운영책임자(President and COO)로 재직했고, 이전에는 Takeda Ventures에서 종양세포치료제 개발을 이끌었으며 Sanofi Genzyme, Roche, Eli Lilly, Syndax에서 고위직을 역임했습니다.
회사는 이사회 강화를 통해 MT-601이라는 리드 자산과 APOLLO 프로그램이 CAR 재발성 확산형 대형 B세포 림프종(DLBCL) 환자에서 잠재적 결정적 연구를 향해 나아가는 데 도움이 될 것이라고 밝혔습니다.
Marker Therapeutics (Nasdaq: MRKR) a annoncé la nomination de Kathryn Penkus Corzo au conseil d’administration, à compter du 1er novembre 2025.
Mme Penkus Corzo apporte plus de 30 ans de leadership dans l’industrie biopharmaceutique, couvrant la R&D, le développement clinique, les approbations réglementaires, la commercialisation et la stratégie d’entreprise. Elle était récemment Présidente et COO de bit.bio et a auparavant dirigé le développement de thérapies cellulaires en oncologie chez Takeda Ventures, avec des postes de direction chez Sanofi Genzyme, Roche, Eli Lilly et Syndax.
La direction a déclaré que cette nomination renforce le conseil alors que Marker fait progresser son actif principal MT-601 et le programme APOLLO vers une étude potentielle pivot chez les patients atteints de lymphome diffus à grandes cellules B (DLBCL) récidivant au CAR.
Marker Therapeutics (Nasdaq: MRKR) gab bekannt, dass Kathryn Penkus Corzo zum Vorstand berufen wurde, mit Wirkung zum 1. November 2025.
Frau Penkus Corzo bringt mehr als 30 Jahre Führungserfahrung in der Biopharma-Branche in Bereichen von F&E, klinischer Entwicklung, behördlichen Zulassungen, Kommerzialisierung und Unternehmensstrategie mit. Zuletzt war sie Präsidentin und COO bei bit.bio und leitete zuvor die Entwicklung von onkologischen Zelltherapien bei Takeda Ventures, mit leitenden Positionen bei Sanofi Genzyme, Roche, Eli Lilly und Syndax.
Die Unternehmensführung erklärte, dass die Ernennung den Vorstand stärkt, während Marker sein führendes Asset MT-601 und das APOLLO-Programm vorantreibt, um eine potenzielle pivotal-Studie bei CAR-rezidivierendem diffusen großzelligem B-Zell-Lymphom (DLBCL) zu ermöglichen.
Marker Therapeutics (Nasdaq: MRKR) أعلنت عن تعيين كاثرين بنكس كورزو في مجلس إدارتها، اعتباراً من 1 نوفمبر 2025.
السيدة بنكس كورزو تجلب أكثر من 30 عاماً من القيادة في مجال الأحياء الدوائية عبر البحث والتطوير، التطوير العلاجي، الموافقات التنظيمية، التسويق والاستراتيجية المؤسسية. خدمَت مؤخرًا كرئيسة ومديرة عمليات في bit.bio وقادت سابقًا تطوير العلاج بالخلايا المناعية في الأورام في Takeda Ventures، مع مناصب عليا في Sanofi Genzyme وRoche وEli Lilly وSyndax.
قالت قيادة الشركة إن التعيين يعزز المجلس مع تقدّم Marker في أداة MT-601 وبرنامج APOLLO نحو دراسة حاسمة محتملة لدى المرضى المصابين بسرطان اللمفوما كبير الخلايا B المعاد CAR-jocking.
- Board seat filled effective Nov 1, 2025
- Adds 30+ years biopharma leadership experience
- Brings commercialization and cell therapy expertise from bit.bio and Takeda
- None.
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025.
Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and indications. Most recently, Ms. Penkus Corzo served as President and Chief Operating Officer at bit.bio Ltd, a biotech company pioneering the use of induced pluripotent stem cells (iPSCs) for human health. During her tenure, she built capabilities to expand the company’s portfolio of commercial products and therapeutic programs and established scalable operations contributing to value generation and revenue growth.
Prior to bit.bio, Ms. Penkus Corzo was Head of Oncology Cell Therapy Development and Partner at Takeda Ventures, where she led the buildout of Takeda’s clinical cell therapy expertise, advancing a portfolio that included CAR-T, CAR-NK, and iPSC-based programs. Earlier in her career, she held senior leadership positions at Sanofi Genzyme, Hoffmann-La Roche, Eli Lilly, and Syndax Pharmaceuticals, where she played key roles in developing and launching multiple global blockbuster cancer therapies.
“We are pleased to welcome Kathryn to our Board of Directors,” said Juan Vera, M.D., President and CEO of Marker Therapeutics. “We believe in the strong clinical benefit we have observed with our lead asset MT-601 and remain committed to advancing the APOLLO program towards a future pivotal study in patients with CAR-relapsed Diffuse Large B Cell Lymphoma (DLBCL). As we are advancing into the next stage of clinical development, we have decided to strategically strengthen our Board of Directors to support this critical next phase. Kathryn’s strong background in oncology and extensive experience in global product commercialization will be invaluable as we continue to advance our clinical and corporate objectives.”
“I am honored to join Marker’s Board of Directors at such a pivotal time for the Company,” said Ms. Penkus Corzo. “Marker’s Multi-Antigen Recognizing (MAR) T cell platform represents a next-generation approach in cell therapy—addressing key limitations of current treatments with the potential to offer improved clinical outcomes to patients with limited therapeutic options. I am inspired by the team’s scientific rigor and commitment to patients, and I look forward to contributing to the advancement of Marker’s clinical programs and long-term growth.”
About MAR-T cells
The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research.
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma or MT-401-OTS for the treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.
Media and Investor Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
FAQ
Who is Kathryn Penkus Corzo and when did she join Marker Therapeutics' board (MRKR)?
What experience does the new Marker (MRKR) director bring in cell therapy and commercialization?
How does Kathryn Penkus Corzo's appointment affect Marker Therapeutics' clinical plans for MT-601 (MRKR)?
What is Marker Therapeutics' lead asset and target indication mentioned with the board appointment (MRKR)?
Will Kathryn Penkus Corzo influence Marker Therapeutics' commercialization strategy (MRKR)?
